J.P. Morgan Reaffirms Their Buy Rating on IQVIA Holdings (IQV)

In a report released on August 8, Anne Samuel from J.P. Morgan maintained a Buy rating on IQVIA Holdings (IQVResearch Report), with a price target of $269.00. The company’s shares closed yesterday at $239.69.

According to TipRanks, Samuel is a 4-star analyst with an average return of 22.6% and a 53.33% success rate. Samuel covers the Technology sector, focusing on stocks such as Allscripts, Health Catalyst, and Convey Holding Parent.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $265.83 average price target, implying a 10.91% upside from current levels. In a report released on July 24, SVB Securities also reiterated a Buy rating on the stock with a $256.00 price target.

See the top stocks recommended by analysts >>

IQV market cap is currently $44.7B and has a P/E ratio of 40.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More on IQV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More